Home › Trials › NCT06426628

Using a nasal swab test to manage patients with pulmonary nodules

Clinical Utility of Management of Patients With CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Observational Veracyte, Inc. · NCT06426628

This study is testing if a nasal swab test can help doctors make better decisions for patients with newly found lung nodules, potentially reducing unnecessary procedures for low-risk cases and speeding up treatment for high-risk cases.

Quick facts

Study typeObservational
Enrollment2400 (estimated)
Ages29 Years to 85 Years
SexAll
SponsorVeracyte, Inc. Industry-sponsored
Locations23 sites (Hartford, Connecticut and 22 other locations)
Trial IDNCT06426628 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate how the Percepta® Nasal Swab test results influence the management of patients with newly identified pulmonary nodules. Participants will be randomly assigned to either a test group, where their test results are shared with their physician, or a control group, where results are not disclosed. The study will assess whether the test reduces the need for invasive procedures in low-risk cases and speeds up treatment for high-risk cases. Approximately 2400 participants will be enrolled across up to 100 centers in the US, with follow-up lasting 24 to 30 months.

Who should consider this trial

Good fit: Ideal candidates are adults aged 29 to 85 with a newly identified pulmonary nodule and a history of smoking.

Not a fit: Patients with active cancer or prior primary lung cancer will not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more personalized and efficient management of pulmonary nodules, potentially reducing unnecessary procedures and expediting treatment for lung cancer.

How similar studies have performed: Other studies have shown promise in using similar diagnostic approaches to improve management of lung nodules, suggesting potential for success in this study.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Able to tolerate nasal epithelial specimen collection
* Signed written Informed Consent obtained
* Subject clinical history available for review by sponsor and regulatory agencies
* New nodule identified on imaging \< 90 days prior to nasal sample collection
* CT report available for index nodule
* 29 - 85 years of age
* Current or former smoker (\>100 cigarettes in a lifetime)
* Pulmonary nodule ≤30 mm detected by CT

Exclusion Criteria:

* Active cancer (other than non-melanoma skin cancer)
* Prior primary lung cancer (prior non-lung cancer acceptable)
* Prior participation in this study (i.e., subjects may not be enrolled more than once)
* Current active treatment with an investigational device or drug
* Patient enrolled or planned to be enrolled in another clinical trial that may influence management of the patient's nodule
* Concurrent or planned use of tools or tests for assigning lung nodule risk of malignancy other than clinically validated risk calculators

Where this trial is running

Hartford, Connecticut and 22 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Pulmonary Nodule, SolitaryLung Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.